Introduction and predictive motif information. The importance of this advantage was made clear when it was recently shown Class I molecules of the major histocompatibility comthat a peptide epitope derived from the tyrosinase proplex (MHC) bind to peptides derived from intracellular tein and recognized by melanoma-reactive CTL differed pathogens or from proteins expressed in tumor cells from the predicted sequence owing to a posttranslaand present them on the cell surface to CD8 ϩ T cells of tional modification of an asparagine residue to aspartic the host immune system (Morrison et al., 1986; Moore acid (Skipper et al., 1996) . This modification did not et al., 1988; Townsend and Bodmer, 1989) . Class I molesignificantly alter interaction with the MHC molecule, cules also present peptides that differ between organ but it had a profound effect on T cell recognition. or bone marrow transplant donor and recipient and can
In the present study, we report the identification of act as minor histocompatibility antigens (mHag) that peptide epitopes that comprise H-Y antigens recognized by HLA-A*0201-restricted specific CTL clones and that also originate from the SMCY protein. The use of
Definition of Epitopes for H-Y-Specific CTL in Naturally Processed Peptides
To verify that this was indeed the peptide naturally expressed on the cell surface and recognized by the T cell, HLA-A*0201 molecules were immunoaffinity purified from the H-Y ϩ B lymphoblastoid cell line (B-LCL) Blk. The associated peptides were extracted in acid and fractionated by reverse-phase HPLC with heptafluorobutyric acid (HFBA) as the organic modifier. Aliquots of each fraction were assayed for their ability to reconstitute the epitope recognized by 1R35 and R416 after incubation with the HLA-A*0201
ϩ , H-Y Ϫ target cell, T2. Interestingly, while both CTL clones recognized the same synthetic peptide, FIDSYICQV, they each recognized components in different HPLC fractions of the naturally processed material. For the R416 clone, a single peak of reconstituting activity was observed in fraction 34, while the 1R35 clone recognized two peaks, one at fractions 35-37 and one at fraction 39 ( Figure 2A ). The active fractions for each clone were pooled separately and rechromatographed with trifluoroacetic acid (TFA) as the organic modifier. A single peak of reconstituting activity was again observed for the R416 clone for the (Mϩ2H) 2ϩ ion of FIDSYICQV at m/z 544 2ϩ in each of the biologically active second dimension fractions. Although collision-activated dissociation (CAD) spectra direct antigen identification technology has demonwere recorded on several different ions of m/z 544 2ϩ strated that these epitopes are posttranslationally modiin these fractions, none corresponded to FIDSYICQV. fied. This newly described modification involves attachThese data suggested either that each CTL clone recogment of a second cysteine residue to a cysteine in the nized a different modified form of this peptide or that primary sequence via a disulfide bond. Data on the reacthe true epitope for either or both CTLs was a naturally tion pathway leading to this modification suggests that processed peptide with a primary sequence different cysteinylated cysteine residues in naturally processed from FIDSYICQV. The most likely site for modification peptides are likely to be quite common.
of FIDSYICQV is the sulfhydryl group of the cysteine residue at position 7. If this modification contains a disulResults fide bond, it should be susceptible to reduction. Indeed, when aliquots of each of the biologically active fractions
Definition of Epitopes for H-Y-Specific CTL
were treated with dithiothreitol (DTT), a new ion at m/z Using Synthetic Peptides 544 2ϩ appeared in the mass chromatogram (compare Two previous reports identified the human and murine top panels in Figures 3A and 3B ) and was confirmed by homologs of the Y-chromosomal protein SMCY as the CAD to be the SMCY sequence FIDSYICQV ( Figure 4A ). source of peptide epitopes recognized by H-Y-specific CTL in the context of HLA-B*0702 and H-2K k , respectively Wang et al., 1995) . This made The Peptide Epitope Recognized by CTL Clone R416 Contains a Cysteinylated SMCY the prime target in searching for H-Y epitopes restricted by other human class I molecules. To this end,
Cysteine Residue
In order to identify the parent peptide that gave rise to a computer program (D'Amaro et al., 1995; Drijfhout et al., 1995) was used to predict and rank peptides from FIDSYICQV upon reduction, mass spectra were searched for signals that disappeared on treatment with DTT. In human SMCY that would bind to HLA-A*0201. From this list, twenty-two peptides whose sequences differed second dimension fractions 43 and 44 of Figure 2B , we found a peptide at m/z 604 2ϩ that disappeared upon from the corresponding sequences encoded by the X-chromosomal homolog, SMCX, were synthesized. treatment of the fraction with DTT (compare middle panels of Figures 3A and 3B ). The CAD spectrum of this When these peptides were tested for their ability to reconstitute the epitope for the HLA-A*0201-restricted, peptide ( Figure 4B ) confirmed the sequence as FIDSY-ICQV with a cysteinylated cysteine residue in position H-Y-specific CD8 ϩ CTL clone, 1R35, only a single 9 residue peptide, FIDSYICQV, was active (Figure 1 ). This 7. The HPLC fractions 43 and 44, in which this peptide was found in the extract of Blk cells, corresponded to peptide was also recognized by the HLA-A*0201-restricted, H-Y-specific CD4
ϩ CTL clone R416 (46% lysis at those recognized by CTL clone R416. Adjacent fractions 42 and 45 neither contained this peptide nor showed 5 ng/ml peptide and an effector: target ratio [E:T] of 9:1). Figure 5A ). Under these conditions, both forms of the peptide were cysteinylated peptide was found only in HPLC fractions that showed R416 sensitizing activity (data not shown).
recognized similarly by the R416 clone. However, the unmodified peptide was recognized about 30-fold better We conclude that the epitope for the H-Y-specific, HLA-A*0201 ϩ CTL clone R416 is FIDSYICQV, where the Cys than the cysteinylated form by the 1R35 clone. In contrast, when target cell incubation with peptide and the has been modified by the attachment of another Cys via a disulfide linkage.
CTL assay were done in cystine-free medium for the (Hunt et al., 1986) have been labeled. In (B), Cys* represents a cysteinylated cysteine residue of 222 mass units.
unmodified peptide and in cystine containing medium by using a 100 pM concentration of the cysteinylated peptide, which is typical of the concentrations required for the cysteinylated peptide, very large differences in the sensitizing activity of the two peptides became apfor reconstitution of several other HLA-A*0201-associated peptide epitopes (Cox et al., 1994; den Haan et al., parent for both CTL clones ( Figure 5B ). Half-maximal target cell lysis by the R416 CTL clone was achieved 1995; Wang et al., 1995) . However, a concentration of 
Cysteinylation Is Not an In Vitro Culture Artifact
Despite the fact that the R416 clone showed preferential on reverse-phase HPLC as did the activity in extracts of cultured B-LCL ( Figure 7 ). CAD spectra recorded on 180 nM of the unmodified peptide was required to the ions of m/z 604 2ϩ in the sensitizing fractions of the achieve the same result. Conversely, half-maximal tarspleen cell extract confirmed the presence of the cysteiget cell lysis by the 1R35 CTL clone was achieved by nylated form of FIDSYICQV (data not shown). This demusing a 3 pM concentration of the unmodified peptide, onstrates that cysteinylated MHC-associated peptides while similar sensitization with the cysteinylated form required 20 nM. These results demonstrate that the 1R35 and R416 clones preferentially recognize the unmodified and cysteinylated forms of FIDSYICQV, respectively. In addition, the less disparate recognition of both forms in normal RPMI-1640 medium containing 0.21 mM cystine demonstrates that peptide cysteinylation by disulfide exchange with cystine can occur rapidly under these conditions.
We also examined whether cysteinylation affected the ability of the peptide to bind to HLA-A*0201 ( Figure 6 ). The unmodified FIDSYICQV showed an IC50 value in an in vitro binding assay with purified HLA-A*0201 of 16 nM, which is indicative of a high affinity interaction. Interestingly, the cysteinylated form of this peptide showed an IC50 of 75 nM, demonstrating that this modification inhibited binding by about 5-fold. Nonetheless, the epitope recognized by each CTL clone.
are produced in vivo and are not an artifact of in vitro 1994b). Since self-tolerance to SMCX will limit the number of SMCY peptides that could give rise to H-Y epiculture.
topes in association with different MHC molecules, it may seem surprising that there is sufficient polymorCysteinylation Occurs in Multiple phism in this sequence to allow the generation of differ-MHC-Associated Peptides ent peptides that are both male-specific and capable of Work related to the identification of naturally processed binding to different MHC molecules. This is likely to be epitopes had led to the discovery of two additional HLAdue to the fact that SMCY is a very large protein (Ͼ1500 A*0101-associated peptides that are derivatized by cysresidues) that differs from the female homolog by over teinylation. These were initially identified because they 200 residues that are relatively uniformly distributed contained an unusual residue mass of 222. In each case, throughout its length. These create the potential to gentreatment of the sample with DTT converted the 222 Da erate a large number of distinct SMCY-specific peptides residue mass to that of cysteine, a net change of 119 as H-Y epitopes. It will be interesting to determine Da. This suggested that the extra mass in the untreated whether the proteins that encode other mHag also share samples resulted from cysteinylation. To confirm this these characteristics. hypothesis, synthetic peptides were prepared and An important result of this study is that the peptide shown to coelute with the naturally occurring material epitope recognized by R416 CTL clone in extracts from and also to have identical CAD spectra. The two peptide HLA-A*0201 molecules has undergone a posttranslasequences are FXDTDTXC*Y and FTESCEXC*Y, where tional modification in which a second cysteine residue (X) refers to Leu or Ile, two residues of identical mass has been covalently linked to a cysteine in the peptide that cannot be distinguished on the triple quadrupole sequence via a disulfide bond. This modification auginstrument, and (C*) refers to a cysteinylated cysteine ments recognition by R416 by over 1000-fold, despite residue. In the case of the latter peptide, while the cystethe fact that it also reduces the binding affinity of the ine at P5 was not cysteinylated, it was amidocarboxylpeptide for HLA-A*0201 by about 5-fold. This same modmethylated. This modification occurred as a result of ified peptide was also identified as the only active spethe inclusion of iodoacetamide as a protease inhibitor cies in HPLC fractions recognized by R416 from 3 differin the buffer used to lyse the B-LCL. This reagent was ent H-Y ϩ , HLA-A*0201 ϩ cell lines, as well as in human not present in the culture medium or in any of the last spleen cells. Taken together, these data clearly define wash or elution buffers used in affinity purification of the epitope recognized by the CD4 ϩ clone, R416, as the the MHC molecules or the elution of the associated cysteinylated form of FIDSYICQV. peptides, indicating that this cysteine residue is accessi-
The results of epitope reconstitution experiments sugble to this modification while it is bound to the MHC gest that one possible mechanism for cysteine modificamolecule. Collectively, these results suggest that cysteition of peptides extracted from cultured cells is disulfide exchange with the 0.21 mM cystine present in the slightly nylation is likely to be a widespread modification of basic RPMI-1640 medium. Although this might suggest MHC-associated peptides, but that both modified and that its occurrence is an artifact of in vitro culture, the unmodified cysteine residues may be present in individpresence of the same cysteinylated species in peptides ual peptides.
extracted from freshly isolated human spleen cells argues against this possibility. Serum also contains up Discussion to 0.1 mM cystine and has a pH that would support cysteinylation of any free cysteine residues accessible In this paper, we have identified a peptide epitope for on the cell surface, so it is possible that the same mechathe H-Y-specific, HLA-A*0201-restricted CTL clone R416 nism of modification could occur in vivo. However, our and provided partial identification information for a secexperiments do not rule out the possibility that cysteinyond epitope for the H-Y-specific, HLA-A*0201-restricted lation might occur before or after peptide binding to CTL clone 1R35. The source of both epitopes appears MHC molecules in the endoplasmic reticulum (ER), since to be SMCY, which was previously identified as the this compartment contains the components that medisource for two other H-Y epitopes restricted by other ate disulfide bond formation and exchange during promurine and human MHC molecules  tein folding. Regardless of the exact mechanism, these Wang et al., 1995) . SMCY is expressed in multiple tissues results suggest that this modified form of the peptide and maps to the same Yq deletion interval as the human is the epitope that stimulated CTL clone R416 in vivo. H-Y antigen controlling locus HY (Cantrell et al., 1992;  Our results also established that two other MHC-asso-O' Reilly et al., 1992) . Interestingly, genetic mapping of ciated peptides have undergone cysteinylation of cystethe mouse Y chromosome has suggested that at least ine residues in their sequences, but that not every cystetwo and up to five distinct loci, including SMCY, encode ine residue is modified in this way. If modification occurs H-Y antigens (King et al., 1994) . With a single exception after peptide binding to the MHC molecule, either in the (Greenfield et al., 1996) , all of the epitopes identified to ER or at the cell surface, then it would depend upon date from both mouse and human have been derived accessibility of the cysteine side chain to aqueous solufrom the SMCY protein. SMCX, a homolog of the SMCY tion. The ability of an uncysteinylated residue to be deprotein located on the X chromosome, is 85% identical rivatized by iodoacetamide while it is bound to MHC to SMCY at the amino acid sequence level. SMCX is molecules suggests that there may be additional conubiquitously expressed by both the active and the inacstraints on cysteinylation, even among accessible resitive X chromosomes in both mice and humans ( (Goulmy et al., 1977; de Bueger et al., 1992a) . ability of peptides to bind and, in some cases, might Both clones recognize H-Y in the context of HLA-A*0201. The clones preclude binding altogether. In sum, we conclude that were cultured by weekly stimulation with irradiated allogeneic PBMC cysteinylation is not rare, but is a highly probable modifiand EBV-transformed B-LCL in RPMI-1640 medium containing 15% cation of any free cysteine residues in peptides that human serum, 3 mM L-glutamine, 1% leucoagglutinin, and 20 U/ml point out of the MHC-binding pocket. ϩ Blk cells, and the bound peptides were separated as described (Hunt et al., 1992; de Bueger et al., 1993; den fractions resulted in the appearance of the unmodified Haan et al., 1995) , except that 1% CHAPS was substituted for NPpeptide. However, we have as yet been unable to identify 40 in all preparative steps. Peptides were eluted from the HLAthe modified parent species. Nonetheless, these results A*0201 molecule with 10% acetic acid, 1% TFA and separated from suggest that the 1R35 CTL clone is specific for a second the HLA-A*0201 heavy chain and ␤2-microglobulin with a 10 kDa distinct modification of the FIDSYICQV peptide. In this Centricon filter (Amicon). Peptides extracts were fractionated by regard, a recent report described a modification involv-HPLC on a reverse-phase C2/C18 column (3 m particles, 120 Å pore ing the addition of an unidentified mass of 102 Da to a size, 2.1 mm inner diameter, 10 cm length), using the Pharmacia Smart System. For the first dimension, separation buffer A was 0.1% cysteine residue in an HLA-A*0201-associated peptide HFBA in water, and buffer B was 0.1% HFBA in acetonitrile. The derived from vinculin (di Marzo Veronese et al., 1996) . gradient was 100% buffer A (0-20 min), 0%-12% buffer B (20-25 Further work will be necessary to establish the source, min), and 12%-50% buffer B (25-80 min) at a flow rate of 100 l/ mechanism, and generality of other modifications of min, and 100 l fractions were collected. For second dimension cysteine residues in class I-associated peptides. to N-linked glycosylation and deglycosylation reactions (39-98 min) at a flow rate of 100 l/min. In both cases, 100 l (Skipper et al., 1996) . Both of these modifications were fractions were collected. detected only through the use of mass spectrometry for peptide sequencing and were not immediately predict- shown to be posttranslationally modified by the attachployed for the analysis of the activity of synthetic peptides. However, ment of carbohydrate side chains (Chicz et al., 1993;  to avoid cysteinylation of peptides during incubation with target Michaelsson et al., 1994) , the extent of which affects T cells and CTL, assays were also performed in cystine-free RPMI-1640 containing 3 mM L-glutamine and 1% BSA, using peptides cell recognition of the peptides (Michaelsson et al., that had been dissolved in Hank's BSS containing 50 mM Hepes 1994), and we think it very likely that class II-associated and 2 mM DTT.
peptides will undergo both asparagine residue-toaspartic acid conversion and cysteinylation. Collec-
Mass Spectrometry
tively, all of these results indicate that the occurrence
Fractions from second dimension HPLC separations that contained of several types of posttranslational modifications of epitope reconstitution activity were analyzed by microcapillary MHC-associated peptides is commonplace and that the HPLC-electrospray ionization mass spectrometry (Hunt et al., 1992) .
influence of these modifications must be taken into acPeptides were loaded onto a C18 microcapillary column (75 m count in attempts to predict immunologically active pepi.d. ϫ 10 cm) and eluted directly into the mass spectrometer with tides from known protein sequences and in the design a gradient of 0%-80% acetonitrile in 0.1% acetic acid over 12 min at 0.5 l/min. In some experiments, samples were reduced by loadof peptide-based immunotherapeutics.
ing them onto the microcapillary column and washing them with 5 l of a 10 mM solution of DTT in ammonium acetate (pH 8.5). Mass Experimental Procedures spectra and CAD mass spectra were recorded on a Finnigan-MAT TSQ-7000 (San Jose, California) triple quadrupole mass spectromeCell Culture ter equipped with an electrospray ion source. Electrospray ionization The CD8 ϩ cytotoxic T cell clone 1R35 and the CD4 ϩ cytotoxic and was accomplished with a voltage differential of 4.6 keV on the needle proliferative T cell clone R416 were derived by limiting dilution culture from the PBMC of a female aplastic anemia patient who had and a sheath liquid consisting of a 70:30 mixture of methanol/ 0.1% acetic acid flowing at 1-2 l/min. Mass spectra were acquired every de Bueger, M., Bakker, A., and Goulmy, E. (1992a) . Existence of mature human CD4ϩ T cells with genuine class I restriction. Eur. J. 1.5 s over the range m/z 300-1400.
Immunol. 22, 875-878.
Synthetic Peptides
de Bueger, M., Rood, J.J., Bakker, A., vanderWoude, F., and Goulmy, Peptides were synthesized by solid-phase FMOC chemistry and E. (1992b) . Tissue distribution of human minor histocompatibility Wang resins on an AMS 422 multiple peptide synthesizer (Gilson antigens: ubiquitous versus restricted tissue distribution indicates Medical Electronics, Middletown, WI). Cysteinylation was accomheterogeneity among human cytotoxic T lymphocyte defined nonplished by incubating synthetic peptides in a solution of aqueous MHC antigens. J. Immunol. 149, 1788-1794. ammonium hydroxide containing excess cystine for 5 min at room de Bueger, M., Verreck, F., Blokland, E., Drijfhout, J.W., Amons, R., temperature. The reaction was terminated by acidifying the solution Koning, F., and Goulmy, E. (1993) . Isolation of an HLA-A2.1 extracted with glacial acetic acid. Peptides were purified to greater than 90% human minor histocompatibility peptide. Eur. J. Immunol. 23, homogeneity by reverse-phase HPLC and characterized by mass 614-618. spectrometry.
den Haan, J.M., Sherman, N.E., Blokland, E., Huczko, E., Koning, F., Drijfhout, J.W., Skipper, J., Shabanowitz, J., Hunt, D.F., EngelClass I Peptide-Binding Assay hard, V.H., and Goulmy, E. (1995) . Identification of a graft versus This was carried out as described (Ruppert et al., 1993; host disease-associated human minor histocompatibility antigen. al., 1994; Sette et al., 1994) . Briefly, affinity-purified HLA-A*0201
Science 268, 1476-1480. molecules were incubated at room temperature with the iodinated indicator peptide, FLPSDYFPSV, and graded doses of test peptides di Marzo Veronese, F., Arnott, D., Barnaba, V., Loftus, D.J., Sakain PBS (pH 7.0) containing 0.05% NP-40, 1 M human ␤2 microglobguchi, K., Thompson, C.B., Salemi, S., Mastroianni, C., Sette, A., ulin (CalBiochem, La Jolla, CA), 1 mM PMSF, 1.3 mM 1,10-phenanShabanowitz, J., et al. (1996) . Autoreactive cytotoxic T lymphocytes throline, 73 M pepstatin A, 8 mM EDTA, and 200 M TLCK. After in human immunodeficiency virus type 1-infected subjects. J. Exp. 48 hr, class I peptide complexes were separated from free peptides Med. 183, 2509-2516. by gel filtration, and the dose of individual test peptides that reduced Drijfhout, J.W., Brandt, R.M., D'Amaro, J., Kast, W.M., and Melief, the binding of indicator peptide by 50% (IC50) was calculated.
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